Neovasc (NASDAQ:NVCN) Earns Sell Rating from Analysts at started coverage on shares of Neovasc (NASDAQ:NVCNGet Rating) (TSE:NVC) in a research note published on Monday morning. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, Bloom Burton restated a buy rating on shares of Neovasc in a report on Friday, August 12th.

Neovasc Stock Performance

NVCN opened at $7.50 on Monday. The company has a current ratio of 8.44, a quick ratio of 8.13 and a debt-to-equity ratio of 0.43. The company’s fifty day moving average price is $6.61 and its two-hundred day moving average price is $6.48. Neovasc has a 1-year low of $4.59 and a 1-year high of $20.00. The company has a market cap of $20.55 million, a price-to-earnings ratio of -0.61 and a beta of 1.96.

Neovasc Company Profile

(Get Rating)

Neovasc Inc, a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina.

Featured Articles

Receive News & Ratings for Neovasc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neovasc and related companies with's FREE daily email newsletter.